LLY
LLY — Healthcare
Graham: 12
Buffett: 48
Lynch: 38
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25...
Price ?
1058.18
Market Cap ?
948.6B
P/E ?
46.09
P/B ?
39.84
Div Yield ?
0.57%
52W Range ?
623.78 - 1133.95
200W MA ?
633.3
12
Graham-style buying rate (0-100)
Criteria breakdown
- ✓ Company size sufficient (large-cap) ? $948,612,694,016 — Uses market cap >= $2B as proxy
- ? Solid financial condition (CR>=2; LT debt <= NCAV) ? CR=? | D/E=1.79 — Partial: checks current ratio; LT debt vs NCAV unavailable
- ✗ Uninterrupted dividends for 20 years ?
- ✗ No losses in last 10 years ? 10y window
- ✓ EPS growth >= 33% over 10 years ? ~2502%
- ✗ Price-to-Book (P/B) <= 1.5 ? 39.84
- ✗ Price-to-Earnings (P/E) <= 15 ? 46.1 — Uses trailing P/E as proxy for 3y avg EPS
- ✗ Combined formula (P/E * P/B) <= 22.5 ? 1836.2
- ✗ Margin of safety >= 20% ? -502% — Intrinsic = EPS * 15
- ✗ High ROE maintained without excessive debt ? ROE=108.3% | D/E=1.79 — Approximate threshold ROE = 15%, D/E = 1.0
What is evaluated (Graham):
- Valuation discipline and buying below intrinsic value.
- Financial resilience: liquidity and prudent leverage.
- Consistent dividends and earnings over long horizons.
"The intelligent investor is a realist who sells to optimists and buys from pessimists." — Benjamin Graham
48
Buffett-style buying rate (0-100)
Criteria breakdown
- ? Positive and growing FCF (multi-year) ? — Insufficient history
- ? ROIC >= 12% sustained ? — Data not available
- ✓ High ROE (proxy for durable advantages) ? 108.3% — Consistency over years not checked
- ✓ Net profit margin >= 10% ? 31.7% — Derived from available financial filings
- ✗ Conservative leverage (D/E <= 1.0) ? 1.79
- ✓ Sustainable shareholder returns (dividend > 0%) ? 0.57% — Does not assess buybacks or payout safety
What is evaluated (Buffett):
- Durable advantages: high ROE, healthy margins.
- Balance discipline and shareholder friendly capital use.
- Positive free cash flow and efficient reinvestment.
"It is far better to buy a wonderful company at a fair price than a fair company at a wonderful price." — Warren Buffett
38
Lynch-style buying rate (0-100)
Criteria breakdown
- ✗ PEG ratio (P/E / growth) <= 1.0 ? 3.16
- ✓ Positive multi-year EPS growth (per-year >= 10%) ? ~14.6%/yr
- ✗ Conservative leverage (D/E <= 0.5) ? 1.79
- ✓ Sustainable profitability (net margin >= 5%) ? 31.7%
- ✗ Earnings stability (no losses in 10y) ? 10y window
What is evaluated (Lynch):
- Growth at a reasonable price (PEG and EPS CAGR).
- Durable earnings with limited drawdowns.
- Conservative balance sheet and baseline profitability.
"Know what you own, and know why you own it." — Peter Lynch